Enteropathy-Associated T-Cell Lymphoma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-EATL |
|---|---|
| Type | Disease |
| Aliases | EATLType I EATLЕнтеропатія-асоційована T-клітинна лімфома |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9717/3 |
|---|---|
| icd_10 | C86.2 |
| who_classification | Mature T-cell and NK-cell neoplasms — Enteropathy-associated T-cell lymphoma per WHO 5th ed. |
Notes
STUB. Exclude MEITL — separate entity з γδ TCR + CD56+ phenotype. Surgical resection common у presentation (perforation). HLA-DQ2/DQ8 testing підтверджує celiac association.
Used By
Algorithms
ALGO-EATL-1L- ALGO-EATL-1L
Indication
IND-CELIAC-REFRACTORY-EATL-PREVENTION-OBSERVATION- IND-CELIAC-REFRACTORY-EATL-PREVENTION-OBSERVATIONIND-CELIAC-REFRACTORY-EATL-PREVENTION-SURVEILLANCE- IND-CELIAC-REFRACTORY-EATL-PREVENTION-SURVEILLANCEIND-EATL-1L-CHOEP-AUTOSCT- IND-EATL-1L-CHOEP-AUTOSCTIND-EATL-2L-ICE- IND-EATL-2L-ICE
Questionnaires
QUEST-EATL-1L-STUB- Enteropathy-Associated T-Cell Lymphoma — first line
Red flag
RF-CELIAC-REFRACTORY-EATL-PREVENTION- Refractory celiac disease — defined as persistent villous atrophy despite strict gluten-f...RF-EATL-FRAILTY-AGE- Age >70 OR ECOG ≥3 — CHOEP intensity + autoSCT consolidation poorly tolerated; CHOP-based...RF-EATL-HIGH-RISK-BIOLOGY- Type II EATL (monomorphic epitheliotropic intestinal T-cell lymphoma) per WHO classificat...RF-EATL-INFECTION-SCREENING- HBV/HCV/HIV/CMV serology + Strongyloides screen pre-CHOEP (immigrants from endemic areas)...RF-EATL-ORGAN-DYSFUNCTION- Bowel perforation, severe malabsorption (albumin <2.5 g/dL), or surgical complication — d...RF-EATL-TRANSFORMATION-PROGRESSION- Refractory disease at end-of-induction (no CR/PR after 4 cycles CHOEP) OR rapid relapse —...
Sources
SRC-ESMO-PTCL-2024- ESMO Clinical Practice Guideline on Peripheral T-cell Lymphomas